Chia Tai Enterprises International AI Stock Analysis
Want to see HK:3839 full AI Analyst Report?
Chia Tai Enterprises International (3839) AI Stock Analysis
Chia Tai Enterprises International
(HKEX:3839)
The overall score of 70 is primarily driven by robust financial performance and an attractive valuation, tempered significantly by weak technical momentum. The company has demonstrated exceptional top-line growth, successful cash flow turnaround, and maintains a highly stable balance sheet, making its 9.89 P/E ratio compelling. However, the stock is technically pressured, trading below all major moving averages with a negative MACD, indicating that while fundamentals are strong, prevailing market sentiment remains bearish.
Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 270.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 62.45K
- Price to Earnings (P/E)
- 11.3
- Beta (1Y)
- 1.08
- Revenue Growth
- -22.78%
- EPS Growth
- -32.03%
- Country
- Hong Kong
- Employees
- 900
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Chia Tai Enterprises International Business Overview & Revenue Model
Company Description
CPBIO Holding Company Limited produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's operations are divided into tw...
How the Company Makes Money
The company makes money primarily by selling and distributing animal health and related agribusiness products and services. Key revenue streams typically include: (1) product sales to farms, distributors, and veterinary channels (e.g., animal health...
Chia Tai Enterprises International Financial Statement Overview
Summary
The company shows strong fundamental health with explosive revenue growth and a return to solid profitability in 2025. It boasts a conservative balance sheet with a low debt-to-equity ratio of 0.17 and improving free cash flow generation, though a multi-year trend of gross margin compression remains a notable headwind.
Income Statement
78PositiveBalance Sheet
82Very PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 424.03M | 536.71M | 307.75M | 173.98M | 159.24M | 142.41M |
| Gross Profit | 70.39M | 77.55M | 48.93M | 30.18M | 39.19M | 34.76M |
| EBITDA | 38.91M | 48.38M | 19.29M | 11.29M | 5.17M | 12.52M |
| Net Income | 24.44M | 32.10M | 11.17M | 2.55M | -6.68M | 19.56M |
Balance Sheet | ||||||
| Total Assets | 505.27M | 461.60M | 422.21M | 377.37M | 350.58M | 365.22M |
| Cash, Cash Equivalents and Short-Term Investments | 37.25M | 39.83M | 32.38M | 37.61M | 30.86M | 31.09M |
| Total Debt | 75.56M | 47.87M | 69.17M | 78.17M | 49.10M | 42.61M |
| Total Liabilities | 179.05M | 153.76M | 161.70M | 125.36M | 94.83M | 81.69M |
| Stockholders Equity | 293.73M | 277.11M | 234.77M | 228.43M | 230.85M | 253.06M |
Cash Flow | ||||||
| Free Cash Flow | 0 | 28.04M | -2.56M | -27.17M | -10.38M | -28.46M |
| Operating Cash Flow | 0 | 34.33M | 11.29M | -16.06M | 5.63M | -10.91M |
| Investing Cash Flow | 0 | -2.79M | -9.27M | -7.14M | -15.64M | -9.84M |
| Financing Cash Flow | 0 | -24.38M | -7.07M | 30.23M | 10.38M | 19.36M |
Chia Tai Enterprises International Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3839, the sentiment is Negative. The current price of 7.24 is below the 20-day moving average (MA) of 7.62, below the 50-day MA of 7.91, and below the 200-day MA of 7.95, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 32.94 is Neutral, neither overbought nor oversold. The STOCH value of 79.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3839.
Chia Tai Enterprises International Peers Comparison
Overall Rating
HK:383970Outperform
HK:095068Neutral
HK:051262Neutral
HK:089758.6Neutral
HK:057058Neutral
HK:393354Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | HKD 1.94B | 11.30 | 7.14% | ― | -22.78% | -32.03% | |
| 68Neutral | HKD 588.84M | 3.56 | 8.02% | 5.75% | 7.05% | 22.46% | |
| 62Neutral | HKD 14.78B | 12.67 | 6.61% | 4.16% | 7.35% | -45.49% | |
| 59Neutral | HKD 390.03M | 100.00 | 0.34% | ― | -8.30% | -44.44% | |
| 58Neutral | HKD 5.59B | -4.47 | -4.98% | 0.32% | -15.80% | -298.94% | |
| 54Neutral | HKD 14.09B | 21.07 | 3.12% | 6.89% | -12.86% | -83.10% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3839 | Chia Tai Enterprises International | 7.24 | 0.98 | 15.65% | |
| HK:3933 | The United Laboratories International | 6.88 | -4.75 | -40.80% | |
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.08 | -1.23 | -53.03% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.06 | -14.29% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.00 | -0.60 | -37.42% | |
| HK:0512 | Grand Pharmaceutical Group Limited | 4.06 | -3.85 | -48.65% |
Chia Tai Enterprises International Corporate Events
CPBIO Reports Unaudited Nine-Month 2026 Results
CPBIO Holding Company Limited reported unaudited consolidated results for the nine months ended 30 September 2026. Revenue was US$331.617 million, down from US$430.536 million a year earlier, while gross profit fell to US$53.739 million from US$59.59...
CPBIO Shareholders Approve 2026 HOEL Purchase Agreement
CPBIO Holding Company Limited’s release does not provide information on its industry, products or market focus.Shareholders approved the 2026 Master HOEL Purchase Agreement, related transactions and annual caps at a special general meeting on 4 Novem...
CPBIO Sets November Board Meeting to Approve Nine-Month Unaudited Results
CPBIO Holding Company Limited has scheduled a board meeting for 11 November 2026 to review and approve the unaudited financial results of the company and its subsidiaries for the nine months ended 30 September 2026. The announcement signals the upcom...
CPBIO Calls Special Meeting to Approve HOEL Supply Agreement Caps
CPBIO Holding Company Limited has called a special general meeting in Hong Kong on 4 November 2026 for shareholders to vote on approving and ratifying the 2026 Master HOEL Purchase Agreement. The agreement covers the ongoing supply of CPBIO Products...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026
